Yuanlin Wu

Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021

Tingting Jiang, Hui Su, Jing Xu et al. · Therapeutic Advances in Drug Safety · 2024 · 26 citations · Full text

Pharmacy, Pharmacology, Clinical Epidemiology +16

CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC)

Yongfu Wang, Yuanlin Wu, Shaoqiang Xie · Bioengineered · 2022 · 20 citations · Full text

Medicine, Molecular Biology, Oncology +17

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system

Tingting Jiang, Hui Su, Yanping Li et al. · Frontiers in Pharmacology · 2022 · 19 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China

Guiyuan Xiang, Tingting Jiang, Lanlan Gan et al. · Frontiers in Immunology · 2023 · 19 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +16

Tumor-promoting roles of HMMR in lung adenocarcinoma

Qihao Wang, Guomin Wu, Linhai Fu et al. · Mutation research. Fundamental and molecular mechanisms of mutagenesis · 2022 · 11 citations

Medicine, Cancer Biology, Oncology +14